Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Total Non-Current Liabilities readings, the most recent being $15.4 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 67.13% to $15.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.4 million, a 67.13% increase, with the full-year FY2025 number at $15.4 million, up 67.13% from a year prior.
  • Total Non-Current Liabilities hit $15.4 million in Q4 2025 for Avalo Therapeutics, down from $33.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $219.1 million in Q1 2024 to a low of $8.1 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $36.5 million (2022), compared with a mean of $46.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 675.46% in 2024 and later crashed 92.87% in 2025.
  • Avalo Therapeutics' Total Non-Current Liabilities stood at $57.1 million in 2021, then dropped by 25.49% to $42.6 million in 2022, then tumbled by 80.88% to $8.1 million in 2023, then increased by 13.28% to $9.2 million in 2024, then soared by 67.13% to $15.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $15.4 million (Q4 2025), $33.4 million (Q3 2025), and $21.8 million (Q2 2025) per Business Quant data.